EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Lipid and glucose abnormalities and associated factors among children living with HIV in Asia

Tulathip Suwanlerk iD, Dhanushi Rupasinghe, Watsamon Jantarabenjakul, Vu T An, Jeremy L Ross, Azar Kariminia, Nguyen Van Lam, Aarti Kinikar, Pradthana Ounchanum, Thanyawee Puthanakit, Nik K Nik Yusoff, Pagakrong Lumbiganon und 12 weitere

Antiviral Therapy · 2023

DOI: 10.1177/13596535231170751 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antiviral Therapy, 2023. Verfasst von Tulathip Suwanlerk und 23 weiteren Autor:innen. Beteiligte Einrichtung: TREAT Asia, amfAR - The Foundation for AIDS Research, Bangkok, Thailand. Hauptthemen laut MEDLINE: Hypercholesterolemia, Dyslipidemias, Hyperlipidemias, HIV Infections. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIAID NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Children living with HIV (CLHIV) on prolonged antiretroviral therapy (ART) are at risk for lipid and glucose abnormalities. Prevalence and associated factors were assessed in a multicentre, Asian longitudinal paediatric cohort.

Methods

CLHIV were considered to have lipid or glucose abnormalities if they had total cholesterol ≥200 mg/dL, high-density lipoprotein (HDL) ≤35 mg/dL, low-density lipoprotein (LDL) ≥100 mg/dL, triglycerides (TG) ≥110 mg/dL, or fasting glucose >110 mg/dL. Factors associated with lipid and glucose abnormalities were assessed by logistic regression.

Results

Of 951 CLHIV, 52% were male with a median age of 8.0 (interquartile range [IQR] 5.0–12.0) years at ART start and 15.0 (IQR 12.0–18.0) years at their last clinic visit. 89% acquired HIV perinatally, and 30% had ever used protease inhibitors (PIs). Overall, 225 (24%) had hypercholesterolemia, 105 (27%) low HDL, 213 (58%) high LDL, 369 (54%) hypertriglyceridemia, and 130 (17%) hyperglycemia. Hypercholesterolemia was more likely among females (versus males, aOR 1.93, 95% CI 1.40–2.67). Current PIs use was associated with hypercholesterolemia (current use: aOR 1.54, 95% CI 1.09–2.20); low HDL (current use: aOR 3.16, 95% CI 1.94–5.15; prior use: aOR 10.55, 95% CI 2.53–43.95); hypertriglyceridemia (current use: aOR 3.90, 95% CI 2.65–5.74; prior use: aOR 2.89, 95% CI 1.31–6.39); high LDL (current use: aOR 1.74, 95% CI 1.09–2.76); and hyperglycemia (prior use: aOR 2.43, 95% CI 1.42–4.18).

Conclusion

More than half and one-fifth of CLHIV have dyslipidemia and hyperglycemia, respectively. Routine paediatric HIV care should include metabolic monitoring. The association between PIs use and dyslipidemia emphasizes the importance of rapidly transitioning to integrase inhibitor-containing regimens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypercholesterolemiaDyslipidemiasHyperlipidemiasHIV InfectionsHyperglycemiaHypertriglyceridemiaFemaleHumansMaleChildChild, PreschoolGlucoseTriglyceridesLipoproteins, LDLAsiaCholesterol, HDL

Stichwörter der Autor:innen

Asiachildren living with HIVlipid and glucose abnormalities

Substanzen

GlucoseTriglyceridesLipoproteins, LDLCholesterol, HDL

Autor:innen und Institutionen

  • TREAT Asia, amfAR - The Foundation for AIDS Research, Bangkok, Thailand.
  • The Kirby Institute, UNSW Sydney, Sydney, Australia.
  • Department of Pediatrics, Faculty of Medicine and Center of Excellence for Pediatric Infectious Diseases and Vaccines, Chulalongkorn University, Bangkok, Thailand.
  • Infectious Diseases Department, Children's Hospital 2, Ho Chi Minh City, Vietnam.
  • Infectious Diseases Department, National Hospital of Pediatrics, Hanoi, Vietnam.
  • BJ Medical College and Sassoon General Hospitals, Maharashtra, India.

ORCID-Profile: Tulathip Suwanlerk

Förderung

  • NIAID NIH HHS
  • National Institutes of Health

Zitieren

APA

Suwanlerk, T., Rupasinghe, D., Jantarabenjakul, W., An, V. T., Ross, J. L., Kariminia, A., Van Lam, N., Kinikar, A., Ounchanum, P., Puthanakit, T., Nik Yusoff, N. K., Lumbiganon, P., Chokephaibulkit, K., Viet, D. C., Sudjaritruk, T., Moy, F. S., Wati, D. K., Mohamed, T. J., Nallusamy, R., …, & TREAT Asia pediatric HIV Observational Database (TApHOD) (2023). Lipid and glucose abnormalities and associated factors among children living with HIV in Asia. Antiviral Therapy. https://doi.org/10.1177/13596535231170751

Vancouver

Suwanlerk T, Rupasinghe D, Jantarabenjakul W, An VT, Ross JL, Kariminia A, et al. Lipid and glucose abnormalities and associated factors among children living with HIV in Asia. Antiviral Therapy. 2023. doi:10.1177/13596535231170751

BibTeX
@article{Suwanlerk2023,
  author = {Suwanlerk, Tulathip and Rupasinghe, Dhanushi and Jantarabenjakul, Watsamon and An, Vu T and Ross, Jeremy L and Kariminia, Azar and Van Lam, Nguyen and Kinikar, Aarti and Ounchanum, Pradthana and Puthanakit, Thanyawee and Nik Yusoff, Nik K and Lumbiganon, Pagakrong and Chokephaibulkit, Kulkanya and Viet, Do C and Sudjaritruk, Tavitiya and Moy, Fong S and Wati, Dewi K and Mohamed, Thahira J and Nallusamy, Revathy and Kumarasamy, Nagalingeswaran and Khol, Vohith and Khanh, Truong H and Kurniati, Nia and TREAT Asia pediatric HIV Observational Database (TApHOD), TREAT Asia pediatric HIV Observational Database (TApHOD)},
  title = {Lipid and glucose abnormalities and associated factors among children living with HIV in Asia},
  journal = {Antiviral Therapy},
  year = {2023},
  doi = {10.1177/13596535231170751}
}
Kostenlos starten →